Caribou Biosciences CLO sold $13,598 in CRBU stock
#Caribou Biosciences #CRBU stock #Barbara McClung #Insider trading #CAR-T cell therapies #Clear Street #Biotechnology stocks
📌 Key Takeaways
- Caribou Biosciences CLO sold $13,598 worth of company stock
- The sale was specifically for tax obligations related to restricted stock units
- CRBU stock has surged 32% in the past week and 73% over the past year
- Clear Street initiated coverage with a Buy rating and $13 price target
- The company is developing promising off-the-shelf allogeneic CAR-T cell therapies
📖 Full Retelling
Barbara G. McClung, Chief Legal Officer of Caribou Biosciences (NASDAQ:CRBU), sold 6,938 shares of common stock on February 24, 2026, for $1.96 per share totaling $13,598 in a transaction reported to the Securities and Exchange Commission, to cover tax obligations related to the vesting of restricted stock units. Despite this insider sale, the stock has shown remarkable performance, climbing to $2.14 after the transaction, reflecting a 32% surge over the past week and a 73% gain over the past year. McClung's recent activities also include acquiring 45,000 shares of Caribou Biosciences common stock on February 20, 2026, with a value of $0, representing restricted stock units that will vest in four equal annual installments beginning February 20, 2027. Additionally, on the same day, she was granted options to purchase 202,500 shares of common stock at an exercise price of $1.80, with these options vesting monthly and reaching full vesting by February 20, 2030. The company has also attracted positive analyst attention, with Clear Street initiating coverage on Caribou Biosciences with a Buy rating and setting a price target of $13.00, expressing particular optimism regarding Caribou's development of off-the-shelf allogeneic CAR-T cell therapies, which are believed to be well-positioned for commercial competition in the market.
🏷️ Themes
Insider Trading, Biotechnology, Stock Market Performance
📚 Related People & Topics
Insider trading
Trading using nonpublic information
# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...
Rachel Haurwitz
American biochemist (born 1985)
Rachel Elizabeth Haurwitz (born May 20, 1985) is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a genome editing company.
Entity Intersection Graph
Connections for Insider trading:
🌐
SEC filing
5 shared
👤
New York Stock Exchange
4 shared
👤
Rachel Haurwitz
2 shared
🌐
ZWS
2 shared
🌐
Biopharmaceutical
2 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry AMD stock surges 14% on Meta AI partnership deal Bitcoin slips, wipes out 50% from October record high at session low Wall Street ends higher on tech rebound ahead of State of the Union address Software stocks rebound as Anthropic partnerships ease AI disruption fears (South Africa Philippines Nigeria) Caribou Biosciences CLO sold $13,598 in CRBU stock By Investing.com Insider Trading Published 02/24/2026, 09:46 PM Caribou Biosciences CLO sold $13,598 in CRBU stock 0 CRBU 11.46% Barbara G. McClung, Chief Legal Officer of Caribou Biosciences NASDAQ:CRBU, sold 6,938 shares of common stock on February 24, 2026, for $1.96 per share, totaling $13,598. The stock has since climbed to $2.14, reflecting a 32% surge over the past week and a 73% gain over the past year. According to a Form 4 filing with the Securities and Exchange Commission, the transaction was to cover tax obligations related to the vesting of restricted stock units. On February 20, 2026, McClung also acquired 45,000 shares of Caribou Biosciences common stock with a value of $0. These shares represent restricted stock units that vest in four equal annual installments beginning February 20, 2027. Additionally, on the same day, McClung was granted options to purchase 202,500 shares of common stock at an exercise price of $1.80. These options vest monthly, with full vesting by February 20, 2030. According to InvestingPro analysis, the stock currently trades below its Fair Value, and investors can access a comprehensive Pro Research Report for deeper insights into CRBU’s prospects. In other recent news, Clear Street has initiated coverage on Caribou Biosciences with a Buy rating. The firm set a price target of $13.00, indicating confidence in the company’s future performance. Clear Street expressed optimism regarding Caribou’s development of off-the-shelf allogeneic CAR-T cell therapies. These therapies are believed to be well-positioned to compete commer...
Read full article at source